Real-world MS drug study tracks relapse reduction in italian patients

NCT ID NCT06345157

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well ofatumumab (Kesimpta®) works for people with relapsing-remitting multiple sclerosis (RRMS) in real-life settings across Italy. About 379 adults already prescribed the drug will be followed for 12 months to measure relapse rates and thinking speed. The goal is to see if the benefits seen in clinical trials hold up outside of a controlled environment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, RELAPSING-REMITTING

Contacts and locations

Locations

Novartis Investigative Site

Ancona, AN, 60126, Italy
Novartis Investigative Site

L’Aquila, AQ, 67100, Italy
Novartis Investigative Site

Bari, BA, 70124, Italy
Novartis Investigative Site

Bergamo, BG, 24127, Italy
Novartis Investigative Site

Chieti, CH, 66100, Italy
Novartis Investigative Site

Catania, CT, 95123, Italy
Novartis Investigative Site

Catanzaro, CZ, 88100, Italy
Novartis Investigative Site

Cona, FE, 44124, Italy
Novartis Investigative Site

Foggia, FG, 71122, Italy
Novartis Investigative Site

Florence, FI, 50134, Italy
Novartis Investigative Site

Genova, GE, 16132, Italy
Novartis Investigative Site

Pozzilli, IS, 86077, Italy
Novartis Investigative Site

Monza, MB, 20900, Italy
Novartis Investigative Site

Palermo, PA, 90127, Italy
Novartis Investigative Site

Pavia, PV, 27100, Italy
Novartis Investigative Site

Ravenna, RA, 48100, Italy
Novartis Investigative Site

Reggio Calabria, RC, 89124, Italy
Novartis Investigative Site

Roma, RM, 00168, Italy
Novartis Investigative Site

Roma, RM, 00189, Italy
Novartis Investigative Site

Siena, SI, 53100, Italy
Novartis Investigative Site

Sassari, SS, 07100, Italy
Novartis Investigative Site

Trento, TN, 38122, Italy
Novartis Investigative Site

Orbassano, TO, 10043, Italy
Novartis Investigative Site

Torino, TO, 10126, Italy
Novartis Investigative Site

Treviso, TV, 31100, Italy
Novartis Investigative Site

Udine, UD, 33100, Italy
Novartis Investigative Site

Gallarate, VA, 21013, Italy
Novartis Investigative Site

Vicenza, VI, 36100, Italy
Novartis Investigative Site

Naples, 80131, Italy
Novartis Investigative Site

Naples, 80138, Italy
Novartis Investigative Site

Novara, 28100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.